Local
Harbour BioMed Announces NMPA Acceptance of IND Application for Its First AI-Enabled Drug Candidate LET003 for the Treatment of Overweight or Obesity
A Roundtable is a way to meet new people and discuss this article in person at a local coffee shop or other venue.
Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.
Source: Arab Tribune

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Nov. 18, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced…
This excerpt comes from the named source. Read the original for the full reporting.
Read the original at Arab Tribune



